Research question
Glioma is a highly aggressive and complex brain tumor, and it poses significant challenges to public health along with other aging-related diseases. By 2030, the incidence of these diseases is projected to increase dramatically due to the aging population. However, the etiology and pathogenesis of glioma and aging-related diseases remain limited, and effective prevention and treatment strategies are urgently needed.
Objective
To address this problem, the present study aims to employ a multi-omics approach, integrating genomics, transcriptomics, proteomics, metabolomics, and comprehensive epidemiological data. We aim to discover new risk factors, identify potential biomarkers, and elucidate the underlying mechanisms of glioma and aging-related diseases to inform clinical anti-tumor drug development.
Scientific rationale
Glioma is characterized by its rapid growth, high invasiveness, and poor prognosis. Aging-related diseases, such as Alzheimer’s disease, Parkinson’s disease, and cardiovascular diseases, are also becoming increasingly prevalent among the elderly population. These diseases share some common features, such as genetic susceptibility, epigenetic modifications, and chronic inflammation. With the help of multi-omics technologies, we can obtain a comprehensive understanding of the molecular landscape of glioma and aging-related diseases. Integrating these multi-omics data with epidemiological information will enable us to identify novel risk factors, biomarkers, and therapeutic targets for glioma and aging-related diseases. This comprehensive approach will not only advance our understanding of the pathogenesis of these diseases but also facilitate the development of personalized prevention and treatment strategies.
